Health Condition 1: K72- Hepatic failure, not elsewhere classified Health Condition 2: K744- Secondary biliary cirrhosis
Conditions
Interventions
Intervention1: NA: NA
Sponsors
European Foundation for the Study of Chronic Liver Failure
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with the diagnosis of liver cirrhosis 2. subjects who have been hospitalized for acute decomposition of liver cirrhosis and referred to the transplant team 3. Patients who have been informed and signed for informed consent
Exclusion criteria
Exclusion criteria: 1. Acute or subacute liver failure without underlying cirrhosis 2. Patients with hepatocellular carcinoma outside Milan criteria or other active neoplasia 3. Subjects listed for transplantation other than the liver or liver-kidney transplant 4. Subjects with previous liver transplantation 5. Vulnerable population 6. Pregnant and/ or breastfeeding women Patients who cannot provide prior informed consent 7. Patients and team not committed to providing intensive care if needed 8. Patients with relevant comorbidities that could impact the prognosis: Subjects with very severe hepatopulmonary syndrome subjects with severe pulmonary disease obstructive lung disease subjects with chronic kidney disease requiring hemodialysis subjects with severe heart disease subjects with known infection with HIV subjects with neurological or psychiatric disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the 1-year graft and patient survival rate after liver transplant (LT) in ACLF 2/3 with patients with decompensated cirrhosis with ACLF 2 and 3Timepoint: 0,3,6,9,12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify factors in decision-making for listing patients with severe ACLF to transplant team To compare the clinical course of patients with ACLF2/3 with decompensated cirrhosis without ACLF 2/3 To identify predictive factors of death or delisting on the waiting list for patients with ACLF 2 and 3 To identify predictive factors for death after LT To identify and compare post-LT survival rate and Quality of life in patients with ACLF 2/3 with patients with decompensated cirrhosis without ACLF 2/3Timepoint: 0,3,6,9,12 months | — |
Countries
Argentina, Australia, France, Germany, India, Netherlands, Spain, Turkey, United Kingdom, United States of America
Contacts
Public ContactShiran Shetty
Kasturba Medical college
Outcome results
None listed